A Waste of Time?

Pharmaceutical companies have been spending a lot of money on new cancer treatments, but the results have been less than stellar, says Robert Langreth on Forbes' Treatments blog. Pfizer, for example, has been spending a lot of money to develop a cancer drug that, in testing, helps only five percent of lung cancer patients with a particular tumor mutation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.